Grifols Portland Oregon: Don't Donate Until You Read This! (Important Info) - publicvm.com
Nov 26, 2025 · Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of. Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, we. Join our Talent Community to embark on an exciting career journey with Grifols, one of the best biotech companies to work for. You’ll be first to receive job openings that align with your skills and preferences.
The founding of Laboratorios Grifols by Grifols i Roig and his sons, Josep Antoni Grifols i Lucas, a hematologist; and Víctor Grifols i Lucas, a chemist and pharmacist, begins an era of business. For product-related inquiries and medical information about our products, please contact the Grifols office in your country. Based in Los Angeles, we cover the U.S. market where we offer a comprehensive portfolio of Grifols products and services. The company is one of the largest producers of life-saving plasma medicines. Nov 4, 2025 · Press release Grifols reports quarterly revenues of EUR 1,865 million and group profit of EUR 127 million November 4, 2025 Read Release Read Release Show more news Apr 18, 2024 · Grifols acquired the Clayton site in 2011 and, with a mission to improve the health and well-being of people around the world, carried forward the site’s legacy of producing quality products. Grifols is increasingly diversifying its therapeutic approach with a portfolio of innovative non-plasma treatments such as a new class of recombinant protein candidates and small-molecule.
Apr 18, 2024 · Grifols acquired the Clayton site in 2011 and, with a mission to improve the health and well-being of people around the world, carried forward the site’s legacy of producing quality products. Grifols is increasingly diversifying its therapeutic approach with a portfolio of innovative non-plasma treatments such as a new class of recombinant protein candidates and small-molecule.
